Author Archives: Forest Ray PhD

First IPF Patient Enrolled in Phase 3 Study of Tyvaso

The first participant has been enrolled in a Phase 3 trial to evaluate the impact of United Therapeutics’ Tyvaso (inhaled treprostinil) on lung function in adults with idiopathic pulmonary fibrosis (IPF). The trial, TETON (NCT04708782), aims to recruit approximately 396 people ages 40 and older, who…

Failed HIV Therapy May Combat COVID-19-induced PF

An experimental therapy that proved ineffective in treating HIV infections now has shown promising potential at preventing or limiting pulmonary fibrosis (PF) caused by SARS-CoV-2, the virus that causes COVID-19. That finding, from a mouse model of induced PF, was detailed in the study  “Targeting RUNX1…

DWN12088 Fares Well in Study of Healthy Volunteers

DWN12088, an investigational therapy for idiopathic pulmonary fibrosis (IPF), showed promising anti-fibrotic properties and appeared to be safe and well-tolerated in a recently-completed Phase 1 clinical trial that enrolled healthy volunteers. Daewoong Pharmaceutical, the therapy’s developer, now plans to start a Phase 2 trial later this year. “We…

Inhaled Pirfenidone Prevented Lung Function Decline in IPF

High-dose AP01 (inhaled pirfenidone) largely prevented lung function decline and was safe and well-tolerated during the first 24 weeks of a Phase 1/2 clinical study testing its use in patients with idiopathic pulmonary fibrosis (IPF). Avalyn Pharma, the therapy’s developer, presented the results at the 2021…

Compound in Medicinal Herb Shows Anti-fibrotic Potential

Magnesium lithospermate B, a compound found in a traditional Chinese medicinal herb, eased several features of pulmonary fibrosis (PF) in a mouse model of the disorder. According to investigators, the anti-fibrotic effects of this plant compound were comparable to those of Esbriet (pirfenidone), an approved treatment for…

IM156 on Fast Track as IPF Treatment

The U.S. Food and Drug Administration (FDA) granted fast track status to IM156, ImmunoMet Therapeutics’ treatment candidate for idiopathic pulmonary fibrosis (IPF). “Fast track designation is another important milestone for ImmunoMet with the potential to speed our ability to advance IM156 to patients,” Benjamin Cowen PhD, ImmunoMet’s CEO,…

FDA Approves Tyvaso, 1st Treatment Aiding Exercise With PH-ILD

Tyvaso (inhaled treprostinil) has been approved as the first treatment to improve exercise ability in people with pulmonary hypertension associated with interstitial lung disease (PH-ILD) in the U.S. PH-ILD is an umbrella term that encompasses idiopathic pulmonary fibrosis (IPF) and other lung fibrotic-related conditions. “The regulatory approval of…

CohBar IDs Peptide to Advance in Testing as Possible IPF Treatment

CohBar has chosen CB5138-3 as its lead treatment candidate for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, based on its promising safety, efficacy, and drug-like properties in preclinical studies. The company is planning to further test this peptide — a small protein fragment — in early studies…